Actinium Pharmaceuticals Inc. (ATNM) 10.90

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actinium Pharmaceuticals Inc. (ATNM) 10.90 $ATNM

Actinium's shares listed on NYSE MKT to facilitate increased visibility and liquidity
M2 - Thu Mar 27, 5:14AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) revealed on Wednesday that its shares have begun trading as of 26 March 2014 on the NYSE MKT under the symbol "ATNM".

Actinium Commences Trading on NYSE MKT Today under the Symbol ATNM
Business Wire - Wed Mar 26, 8:30AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that its shares have commenced trading today on the NYSE MKT under the symbol "ATNM". The company formerly traded on the OTCQB under the same symbol.

Actinium to Commence Trading on NYSE MKT on March 26, 2014
Business Wire - Tue Mar 25, 9:05AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will commence trading its common shares on the NYSE MKT beginning on March 26, 2014.

Actinium to Present at BioCentury 21st Annual Future Leaders in the Biotech Industry Conference on March 28
Business Wire - Tue Mar 25, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the BioCentury 21st Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 8:30 am Eastern Time.

Actinium to begin trading on NYSE MKT on 26 March 2014
M2 - Tue Mar 25, 4:16AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) disclosed on Monday that it will commence trading on the New York Stock Exchange on 26 March 22014.

Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients
M2 - Tue Mar 25, 4:06AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) said on Monday that it has treated the first patient with Actimab-A drug candidate for newly diagnosed AML patients under its ongoing Phase 1/2 trial.

Actinium to List Common Stock on NYSE MKT
Business Wire - Mon Mar 24, 4:20PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on March 26, 2014. The Company will continue to trade under the symbol "ATNM" but will withdraw its shares from listing on the OTCQB concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.

Actinium Announces Introduction of the New Lot of Lintuzumab into the Clinic
Business Wire - Mon Mar 24, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate manufactured with the new lot of Lintuzumab, the antibody that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of Actimab-A is in newly diagnosed AML patients over the age of 60 in a single arm multicenter trial.

Actinium to Present at 2nd Annual Sachs Cancer Bio Partnering & Investor Forum
Business Wire - Thu Mar 13, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at New York Academy of Sciences, located at 250 Greenwich St, New York, NY, on Wednesday, March 19, 2014 at 2:45 PM ET.

Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013

Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.

Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference
Marketwire - Wed Feb 26, 7:08AM CST
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host an advisory meeting with leading bone marrow transplant experts during the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in Grapevine, Texas on Saturday, March 1, 2014. The Company will present an agreement reached with the Food and Drug Administration (FDA) on the design of a single pivotal Phase III trial for approval of Iomab(TM)-B, Actinium's leading drug candidate. The advisory group will discuss the Iomab(TM)-B Phase III trial design, formation of a Scientific Advisory Board for Iomab(TM)-B and logistics of the Phase III trial.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.

Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica

Global Radiopharmaceuticals Market Insight Research Report
M2 - Tue Feb 11, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8p2r/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly. A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market. Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities. The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018. Report Highlights: - Global Radio Pharmaceuticals Market Overview by Region - Target Patient Base by Region - Radiopharmaceuticals Market Regulation for US, Europe & Canada - Radioisotopes Used in Radiopharmaceuticals - Radiopharmaceutical Clinical Pipeline Insight - Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase Companies Mentioned - AREVA Med - Actinium Pharmaceuticals - Avid Radiopharmaceuticals - Bayer HealthCare Pharmaceuticals - Cardinal Health - GE Healthcare - Immunomedics - Ion Beam Applications - Lantheus Medical Imaging - Lantheus Medical Imaging - Merck & Co - Navidea - Nordion - PETNET Solutions (Siemens Healthcare Global) For more information visit http://www.researchandmarkets.com/research/px8p2r/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Actinium Presenting at the 16th Annual BIO CEO & Investor Conference Today at 1:30 pm ET
Business Wire - Tue Feb 11, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 1:30 pm ET at the 16th Annual BIO CEO & Investor Conference. Dr. Kaushik J. Dave, President and CEO, will present a corporate update.

Actinium to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 16th Annual BIO CEO & Investor Conference from February 10th to 11th, 2014. Dr. Dave will present an overview of the company on Tuesday, February 11, 2014 at 1:30 pm ET.

MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
Marketwire - Thu Jan 30, 7:30AM CST
MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.

Actinium Engages Goodwin Biotechnology to Supply Iomab(TM)-B for Its Phase 3 Clinical Study
Business Wire - Wed Jan 29, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. ("Goodwin"). According to the agreement, Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab(TM)-B. Iomab(TM)-B will be used in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).

Actinium Pharmaceuticals Announces Engagement of MissionIR Investor Relations Services
Marketwire - Wed Jan 15, 7:30AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) (the "Company") today announces that they have engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

XPLR Infrastructure Faces Class Action Lawsuit Outcry

Updated Category News Views 170

Class Action Lawsuit Filed Against XPLR Infrastructure Levi & Korsinsky, LLP has announced a class action lawsuit concerning XPLR Infrastructure, LP, previously known as Nextera Energy Partners, LP. This lawsuit addresses significant concerns regarding securities fraud that impacted numerous investors, particularly those who held shares during the specified time frame....

Continue Reading
PharmAla Reports Impressive Growth and Key Milestones Achieved

Updated Category News Views 291

PharmAla Biotech Holdings Shareholder Update PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has recently shared their financial and operational performance metrics providing insight into their notable achievements up to the end of May 2025. Focusing on the development and distribution of LaNeo™ MDMA, along with other novel...

Continue Reading
Discover the Bold New Batch of Sagamore Spirit Rye Whiskey

Updated Category News Views 387

Discover the Bold New Batch of Sagamore Spirit Rye Whiskey The 100% Maryland-made whiskey is 7-Years-Old and 123 Proof Sagamore Spirit, the celebrated Maryland rye distillery, is introducing a new batch of their award-winning Cask Strength Rye Whiskey. This exceptional spirit boasts a seven-year age profile and carries a robust ABV of 61.5%. The whiskey delights the...

Continue Reading
Stocks to Eye: Ciena, Oracle, and Other Market Movers Ahead

Updated Category News Views 166

Market Trends to Watch This Thursday As U.S. stock futures experience a downward shift, investors are keenly eyeing some significant stocks that could impact market movements today. Among them, several prominent companies are set to announce their earnings, potentially affecting their stock performance and overall market sentiment. Ciena Corp. on Investor's Radar Wall...

Continue Reading
The Perfect Franchise Conference Boosts Industry Engagement

Updated Category News Views 144

The Perfect Franchise Annual Conference: A Catalyst for Growth The Perfect Franchise (TPF), a leader in the realm of franchise consulting and coaching, has seen notable advancements, particularly in the wake of their annual conference. As the franchise industry blooms, this gathering serves not just as an event but as a beacon of growth for both franchise brands and...

Continue Reading